Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
125,5 USD | +0,81% | -3,05% | +15,15% |
31/05 | Trodelvy van Gilead mislukt in onderzoek naar blaaskanker, verlengt de overleving bij longkanker in bescheiden mate | RE |
31/05 | Sectorupdate: Gezondheidszorg | MT |
Officiële publicaties
Dividends | CO | |
Slide show Q1 | CO | |
1st quarter results | CO | |
SEC Filing 8K | CO | |
Proxy Statments | CO | |
Acquisition | CO | |
SEC Filing 10K | CO | |
SEC Filing 8K | CO | |
Slide show results | CO | |
Annual results | CO | |
SEC Filing 8K | CO | |
Dividends | CO | |
Dividends | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-3 | CO | |
Slide show Q3 | CO | |
3rd quarter results | CO | |
SEC Filing 10Q-2 | CO | |
Slide show half-year results | CO | |
1st-half-year results | CO | |
SEC Filing 8K | CO | |
Dividends | CO | |
Shareholders meeting voting results | CO | |
Dividends | CO | |
SEC Filing 4K | CO |
- Beurs
- Aandelen
- Koers MRK
- Nieuws Merck & Co., Inc.
- Officiële publicaties